---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210299"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:55:14.876280+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics Reports Q1 2026 Results; BEAM-302 Pivotal Cohort and Risto-cel BLA on Track

## Summary
- BEAM-302 Phase 1/2 data showed single-dose safety and efficacy; 60 mg selected as optimal dose; global pivotal cohort to start H2 2026.
- Risto-cel (BEAM-101) Phase 1/2 data published in NEJM; BLA submission expected as early as year-end 2026 for sickle cell disease.
- Cash, cash equivalents and marketable securities were $1.2 billion as of March 31, 2026; cash runway into mid-2029.
- Net loss of $94.3 million ($0.91 per share) for Q1 2026, compared to net loss of $108.3 million ($1.23 per share) in Q1 2025.
- IND filing for BEAM-304 in PKU and initial data for BEAM-301 in GSDIa expected in 2026.

## SEC filing metadata
- accession: 0001193125-26-210299
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312526210299/0001193125-26-210299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312526210299/beam-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210299
- JSON: https://secwatch.observer/filing/0001193125-26-210299.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210299.txt

## Source-grounded claims
- claim_id: a262c3859f99ebb9c85b44636b02bfe77f5236f9
  claim: Beam Therapeutics Inc. reported financial results for quarter ended March 31, 2026.
  evidence_excerpt: On May 7, 2026, the Company issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000119312526210299/0001193125-26-210299-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.